Baricitinib is safe and efficacious over 52 weeks as a treatment for severe alopecia areata, according to recent real-world findings, aligning with clinical trial results.1
These conclusions regarding baricitinib’s treatment of alopecia areata resulted from an analysis written by a team of investigators led by Carlo A. Vignolia. Vignolia works at the dermatology unit at IRCCS Humanitas Research Hospital in Milan.
Vignolia et al. noted that although recent research has been limited by shorter lengths of follow-up, findings have supported baricitinib as an option for alopecia treatment in real-world clinical settings.2 Nonetheless, given variable responses among patients, treatment of alopecia areata may necessitate more extended observation periods
“In order to further evaluate the long-term effectiveness and safety…